Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice
Identifieur interne : 001564 ( Main/Exploration ); précédent : 001563; suivant : 001565Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice
Auteurs : K. Montag [Australie] ; M. Gingold [Australie] ; A. Boers [Australie] ; G. Littlejohn [Australie]Source :
- Internal Medicine Journal [ 1444-0903 ] ; 2011-06.
English descriptors
- Teeft :
- Alfred hospital, Arthritis, Arthritis rheum, Autonomic dysfunction, Bdmard, Bdmard therapy, Biologic, Biologic dmard, Conventional dmard, Disease activity, Disease activity score, Disease activity scores, Disease duration, Diseasemodifying drugs, Dmard, Dmard therapy, Drug survival, Joint damage, Large group, Large proportion, Largest proportion, Life tables, Medication, Medicine journal, Methotrexate, Moderate disease activity, Monoclonal antibody, Patient population, Physicians dmards, Real world, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Royal australasian college, Unmet need.
Abstract
Aims: Our aim was to examine the spectrum of disease activity and usage of disease‐modifying anti‐rheumatic drugs (DMARD) in rheumatoid arthritis (RA) patients seen over a period of 12 months in community‐based rheumatology practice. Methods: Data were prospectively collected on 1059 consecutive RA patients who attended two private, community‐based rheumatology clinics from 1 May 2007 to 1 May 2008. Information on patient demographics, medication history and disease activity was collected. Life table graphs were developed to track medication retention over time. Statistical significance was determined by log–rank tests. Results: One thousand and fifty‐nine patients with RA were entered into the database over a 12‐month period. Eight hundred and twenty‐six patients (85%) were treated with single or combination conventional DMARD compared with 159 patients (15%) on a biologic DMARD either alone or in combination. Methotrexate monotherapy was the most commonly prescribed DMARD, used in 41% of patients studied. Almost half (47%) were on combination DMARD therapy. Methotrexate and tumour necrosis factor inhibitors had the highest retention rate over 12 and 30 months since first prescription. A large proportion of patients (47%) had moderate disease activity. Conclusion: Rates of biologic DMARD usage were similar to other studies and the predominance of methotrexate use was also in keeping with current recommendations for management of RA. There appears to be a significant unmet need for improved disease control among RA patients with moderate disease activity, which requires further investigation.
Url:
DOI: 10.1111/j.1445-5994.2010.02240.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F15
- to stream Istex, to step Curation: 000F15
- to stream Istex, to step Checkpoint: 000540
- to stream Main, to step Merge: 001566
- to stream Main, to step Curation: 001564
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice</title><author><name sortKey="Montag, K" sort="Montag, K" uniqKey="Montag K" first="K." last="Montag">K. Montag</name></author><author><name sortKey="Gingold, M" sort="Gingold, M" uniqKey="Gingold M" first="M." last="Gingold">M. Gingold</name></author><author><name sortKey="Boers, A" sort="Boers, A" uniqKey="Boers A" first="A." last="Boers">A. Boers</name></author><author><name sortKey="Littlejohn, G" sort="Littlejohn, G" uniqKey="Littlejohn G" first="G." last="Littlejohn">G. Littlejohn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A72B5703A97CF5BFF6807EBF36BE156CD9BC4A4A</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1445-5994.2010.02240.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-MN755QCH-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000F15</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F15</idno><idno type="wicri:Area/Istex/Curation">000F15</idno><idno type="wicri:Area/Istex/Checkpoint">000540</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000540</idno><idno type="wicri:doubleKey">1444-0903:2011:Montag K:disease:modifying:anti</idno><idno type="wicri:Area/Main/Merge">001566</idno><idno type="wicri:Area/Main/Curation">001564</idno><idno type="wicri:Area/Main/Exploration">001564</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice</title><author><name sortKey="Montag, K" sort="Montag, K" uniqKey="Montag K" first="K." last="Montag">K. Montag</name><affiliation wicri:level="3"><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><wicri:orgArea>Departments of Rheumatology/Medicine, Monash Medical Centre/Monash University</wicri:orgArea></affiliation></author><author><name sortKey="Gingold, M" sort="Gingold, M" uniqKey="Gingold M" first="M." last="Gingold">M. Gingold</name><affiliation wicri:level="3"><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><wicri:orgArea>Departments of Rheumatology/Medicine, Monash Medical Centre/Monash University</wicri:orgArea></affiliation></author><author><name sortKey="Boers, A" sort="Boers, A" uniqKey="Boers A" first="A." last="Boers">A. Boers</name><affiliation wicri:level="3"><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><wicri:orgArea>Departments of Rheumatology/Medicine, Monash Medical Centre/Monash University</wicri:orgArea></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, Latrobe Regional Hospital, Traralgon, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Littlejohn, G" sort="Littlejohn, G" uniqKey="Littlejohn G" first="G." last="Littlejohn">G. Littlejohn</name><affiliation wicri:level="3"><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><wicri:orgArea>Departments of Rheumatology/Medicine, Monash Medical Centre/Monash University</wicri:orgArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Australie</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="ISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><imprint><biblScope unit="vol">41</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="450">450</biblScope><biblScope unit="page" to="455">455</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2011-06">2011-06</date></imprint><idno type="ISSN">1444-0903</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1444-0903</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alfred hospital</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autonomic dysfunction</term><term>Bdmard</term><term>Bdmard therapy</term><term>Biologic</term><term>Biologic dmard</term><term>Conventional dmard</term><term>Disease activity</term><term>Disease activity score</term><term>Disease activity scores</term><term>Disease duration</term><term>Diseasemodifying drugs</term><term>Dmard</term><term>Dmard therapy</term><term>Drug survival</term><term>Joint damage</term><term>Large group</term><term>Large proportion</term><term>Largest proportion</term><term>Life tables</term><term>Medication</term><term>Medicine journal</term><term>Methotrexate</term><term>Moderate disease activity</term><term>Monoclonal antibody</term><term>Patient population</term><term>Physicians dmards</term><term>Real world</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Royal australasian college</term><term>Unmet need</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims: Our aim was to examine the spectrum of disease activity and usage of disease‐modifying anti‐rheumatic drugs (DMARD) in rheumatoid arthritis (RA) patients seen over a period of 12 months in community‐based rheumatology practice. Methods: Data were prospectively collected on 1059 consecutive RA patients who attended two private, community‐based rheumatology clinics from 1 May 2007 to 1 May 2008. Information on patient demographics, medication history and disease activity was collected. Life table graphs were developed to track medication retention over time. Statistical significance was determined by log–rank tests. Results: One thousand and fifty‐nine patients with RA were entered into the database over a 12‐month period. Eight hundred and twenty‐six patients (85%) were treated with single or combination conventional DMARD compared with 159 patients (15%) on a biologic DMARD either alone or in combination. Methotrexate monotherapy was the most commonly prescribed DMARD, used in 41% of patients studied. Almost half (47%) were on combination DMARD therapy. Methotrexate and tumour necrosis factor inhibitors had the highest retention rate over 12 and 30 months since first prescription. A large proportion of patients (47%) had moderate disease activity. Conclusion: Rates of biologic DMARD usage were similar to other studies and the predominance of methotrexate use was also in keeping with current recommendations for management of RA. There appears to be a significant unmet need for improved disease control among RA patients with moderate disease activity, which requires further investigation.</div></front></TEI><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Montag, K" sort="Montag, K" uniqKey="Montag K" first="K." last="Montag">K. Montag</name></region><name sortKey="Boers, A" sort="Boers, A" uniqKey="Boers A" first="A." last="Boers">A. Boers</name><name sortKey="Boers, A" sort="Boers, A" uniqKey="Boers A" first="A." last="Boers">A. Boers</name><name sortKey="Gingold, M" sort="Gingold, M" uniqKey="Gingold M" first="M." last="Gingold">M. Gingold</name><name sortKey="Littlejohn, G" sort="Littlejohn, G" uniqKey="Littlejohn G" first="G." last="Littlejohn">G. Littlejohn</name><name sortKey="Littlejohn, G" sort="Littlejohn, G" uniqKey="Littlejohn G" first="G." last="Littlejohn">G. Littlejohn</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001564 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001564 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A72B5703A97CF5BFF6807EBF36BE156CD9BC4A4A
|texte= Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice
}}
| This area was generated with Dilib version V0.6.33. |  |